Company intelligence / Profile preview

Deebio

Guanghan, Sichuan, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Deebio is a leading Chinese manufacturer and exporter of bio-enzyme active pharmaceutical ingredients (API), serving regulated, global, and US/EU markets with commercial-scale production; it supplies APIs such as kallidinogenase, pepsin, cytochrome c, heparin sodium, and thyroid to clients including major compounders, and is scaling new products with global regulatory registrations, although it received a recent FDA warning letter on data integrity.[1][2][3][5][6][7][8]

Therapeutic areas: EndocrinologyRheumatologyGastroenterologyDermatologyCardiovascular
Modalities: ProteinEnzymeBiologic
Industry: Contract Manufacturing Organization

Partnerships

MEDISCA

Beyond the preview

Go deeper on Deebio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deebio.

Explore the full profile